Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Deals

Eli Lilly Close to Acquiring Verve Therapeutics for Up to USD 1.3 Billion

Fineline Cube Jun 17, 2025

US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to...

Company Drug

Pediatrix Therapeutics Wins Macau Approval for Neffy Epinephrine Nasal Spray

Fineline Cube Jun 17, 2025

China-based Pediatrix Therapeutics announced that it has received marketing approval in Macau for its neffy...

Company Drug

Minova Pharmaceuticals Launches Rongzhi, China’s First Injectable Adipocytolytic Drug

Fineline Cube Jun 17, 2025

Nanjing-based Minova Pharmaceuticals Co., Ltd announced last week that it has received marketing approval from...

Legal / IP

RemeGen Secures 1,827-Day Patent Extension for Telitacicept in China

Fineline Cube Jun 17, 2025

China-based pharmaceutical firm RemeGen (HKG: 9995) announced that the China National Intellectual Property Administration has...

Company Drug

Fujian Cosunter Gains Ethics Approval for Phase III Study of Neracorvir in CHB Patients

Fineline Cube Jun 17, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd. (SHE: 300436) announced that it has received ethical approval...

Company Drug

CDE Accepts NDA for Ark Bio’s Azstarys, a Priority-Reviewed ADHD Treatment

Fineline Cube Jun 17, 2025

China’s Center for Drug Evaluation (CDE) has officially accepted the New Drug Application (NDA) for...

Company Drug

Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918

Fineline Cube Jun 17, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) unveiled 13 research presentations at the 2025 European...

Company Deals

Clover Biopharmaceuticals Terminates Adimmune Influenza Vaccine Pact Over Market Shifts

Fineline Cube Jun 17, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the exercise of unilateral termination rights under its...

Company Drug

Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment

Fineline Cube Jun 17, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...

Policy / Regulatory

China’s NHC Unveils 2025 Healthcare Reforms to Tackle Procurement and Service Irregularities

Fineline Cube Jun 16, 2025

China’s National Health Commission (NHC) has released the 2025 Key Tasks for Rectifying Improper Practices...

Company Deals Medical Device

Thermo Fisher Mulls $4B Diagnostic Business Sale Amid Healthcare Sector Turbulence

Fineline Cube Jun 16, 2025

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) is reported by the Financial...

Company Drug

Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial

Fineline Cube Jun 16, 2025

China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary...

Company Drug

Novo Nordisk Advances Amycretin for Weight Management in Phase III Trials

Fineline Cube Jun 16, 2025

Denmark-based pharmaceutical major Novo Nordisk (NYSE: NVO) announced plans to advance both subcutaneous and oral...

Company Drug

FDA OKs MSD’s Keytruda for Perioperative Head and Neck Cancer Treatment With PD-L1 Expression

Fineline Cube Jun 16, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food...

Company Drug

GSK Seeks EMA Approval to Expand RSV Vaccine Arexvy Use to Adults Aged 18+

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has announced that the European Medicines Agency (EMA)...

Company

UCB Announces Investment in U.S. Biologics Production Facility

Fineline Cube Jun 16, 2025

Belgium-based biopharmaceutical company UCB (EBR: UCB) announced plans to invest in a cutting-edge biologics production...

Company Deals

Gene Solutions Partners with Shenzhen USK Bio to Advance Precision Oncology in Southern China

Fineline Cube Jun 16, 2025

Vietnam-headquartered Gene Solutions announced a Memorandum of Understanding (MOU) with China’s Shenzhen USK Bioscience Co.,...

Company Deals

MRI and Astellas Alliance to Boost Japanese Drug Discovery Startups

Fineline Cube Jun 16, 2025

Japan-based Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (TYO: 4503) announced the signing...

Company Drug

MSD Wins NMPA Approval for Keytruda-Lenvima Combo in Hepatocellular Carcinoma

Fineline Cube Jun 16, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...

Company Deals

Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline

Fineline Cube Jun 16, 2025

Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460),...

Posts pagination

1 … 139 140 141 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.